Revive Therapeutics Ltd
Change company Symbol lookup
Select an option...
RVVTF Revive Therapeutics Ltd
JPM-K JPMorgan Chase & Co
MAX Mediaalpha Inc
BB BlackBerry Ltd
MORN Morningstar Inc
GHYUSiv.P JPM Gbl HY Corpo Bd Multi-Fctr UCITS ETF USD A
DBD Diebold Nixdorf Inc
SHPH Shuttle Pharmaceuticals Holdings Inc
MSGE Madison Square Garden Entertainment Corp
IMMX Immix Biopharma Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Based in Canada
Company profile

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for rare disorders and infectious diseases. The Company is exploring the use of Bucillamine for the treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. Through its subsidiary, Psilocin Pharma Corp., the Company is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. The Company’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the Company was granted Food and Drug Administration (FDA) orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation.

Closing Price
$0.0475
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
178,261

10-day average volume:
496,701
178,261
Historical quotes & splits

Display:

Providers:

UpdateCancel
All providers
Search
Any date
Any date
Last 24 hours
Last 7 days
May 2023
April 2023
March 2023
February 2023
January 2023
December 2022
November 2022
October 2022
September 2022
August 2022
July 2022
June 2022
May 12, 2023
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19(Globe Newswire)
May 02, 2023
Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19(Globe Newswire)
April 18, 2023
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19(Globe Newswire)
April 03, 2023
Revive Therapeutics Advances MDMA Transdermal Patch Development with Purchase of MDMA Supply from PharmAla Biotech(Globe Newswire)
March 28, 2023
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder(Globe Newswire)
March 20, 2023
Revive Therapeutics Provides Update of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19(Globe Newswire)
March 08, 2023
Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.

3rd Party Research Disclosure